DSS (DSS) 10-Q 14 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 04, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-32146
Entity Registrant Name	DSS, INC.
Entity Central Index Key	0000771999
Entity Tax Identification Number	16-1229730
Entity Incorporation, State or Country Code	NY
Entity Address, Address Line One	275 Wiregrass Pkwy
Entity Address, City or Town	West Henrietta
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14586
City Area Code	(585)
Local Phone Number	325-3610
Title of 12(b) Security	Common Stock, $0.02 par value per share
Trading Symbol	DSS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		140,264,250

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 10,033,000	$ 19,290,000
Accounts receivable, net	2,468,000	7,564,000
Inventory	5,300,000	7,721,000
Assets held for sale	1,524,000
Current portion of notes receivable	9,269,000	11,719,000
Prepaid expenses and other current assets	1,199,000	1,700,000
Total current assets	29,793,000	47,994,000
Property, plant and equipment, net	12,438,000	13,391,000
Investment in real estate, net	53,997,000	55,029,000
Other investments	1,163,000	1,534,000
Investment, equity method	139,000	162,000
Marketable securities	11,575,000	27,307,000
Notes receivable	1,112,000	922,000
Non-current assets held for sale	480,000
Other assets	261,000	2,699,000
Right-of-use assets	7,515,000	8,219,000
Goodwill	57,880,000	60,919,000
Other intangible assets, net	28,508,000	30,740,000
Total assets	204,861,000	248,916,000
Current liabilities:
Accounts payable	3,046,000	5,914,000
Accrued expenses and deferred revenue	3,080,000	19,341,000
Other current liabilities	396,000	477,000
Current Liabilities held for sale	1,129,000
Current portion of lease liability	633,000	796,000
Current portion of long-term debt, net	47,206,000	47,161,000
Total current liabilities	55,490,000	73,689,000
Long-term debt, net	7,218,000	10,181,000
Long term lease liability	7,120,000	7,820,000
Non-current liabilities held for sale	59,000
Other long-term liabilities	507,000	507,000
Deferred tax liability	38,000	38,000
Commitments and contingencies (Note 11)
Stockholders’ equity
Common stock, $.02 par value; 200,000,000 shares authorized, 140,264,250 shares issued and outstanding (139,017,172 on December 31, 2022)	2,804,000	2,779,000
Additional paid-in capital	317,369,000	317,126,000
Accumulated deficit	(221,529,000)	(194,343,000)
Total stockholders’ equity	98,644,000	125,562,000
Non-controlling interest in subsidiaries	35,785,000	31,119,000
Total stockholders’ equity	134,429,000	156,681,000
Total liabilities and stockholders’ equity	$ 204,861,000	$ 248,916,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.02	$ 0.02
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	140,264,250	139,017,172
Common stock, shares outstanding	140,264,250	139,017,172

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue:
Total revenue	$ 7,233,000	$ 11,771,000	$ 19,064,000	$ 24,064,000
Cost of revenue:
Printed Products	2,421,000	2,603,000	7,081,000	6,026,000
Securities	1,820,000	2,551,000	4,340,000	5,124,000
Biotechnology	2,000	308,000	63,000	308,000
Direct Marketing	516,000	1,990,000	1,806,000	4,127,000
Others	73,000	218,000	75,000	700,000
Selling, general and administrative (including stock-based compensation)	8,851,000	15,283,000	17,824,000	25,639,000
Total costs and expenses	13,683,000	22,953,000	31,189,000	41,924,000
Operating loss	(6,450,000)	(11,182,000)	(12,125,000)	(17,860,000)
Other income (expense):
Interest income	407,000	139,000	538,000	295,000
Dividend income	8,000		12,000
Other income (expense)	147,000	2,344,000	175,000	576,000
Interest expense	(138,000)	(121,000)	(388,000)	(1,499,000)
Gain on extinguishment of debt		110,000		110,000
Loss on equity method investment	(18,000)	(99,000)	(22,000)	(211,000)
(Loss)/gain on investments	(27,922,000)	3,399,000	(30,790,000)	3,823,000
Provision for loan losses	(3,757,000)		(3,757,000)
Gain on sale of assets				405,000
Loss from continuing operations before income taxes	(37,723,000)	(5,410,000)	(46,357,000)	(14,361,000)
Income tax benefit (loss)
Net loss	(37,723,000)	(5,410,000)	(46,357,000)	(14,361,000)
(Income)/loss from continuing operations attributed to noncontrolling interest	(200,000)	758,000	398,000	1,661,000
Net loss attributable to common stockholders	$ (37,923,000)	$ (4,652,000)	$ (45,959,000)	$ (12,700,000)
Loss per common share:
Basic	$ (0.27)	$ (0.05)	$ (0.33)	$ (0.15)
Diluted	$ (0.27)	$ (0.05)	$ (0.33)	$ (0.15)
Shares used in computing loss per common share:
Basic	140,140,913	34,888,054	139,579,043	85,641,957
Diluted	140,140,913	34,888,054	139,579,043	85,641,957
Printed Products [Member]
Revenue:
Total revenue	$ 3,626,000	$ 4,048,000	$ 9,661,000	$ 7,617,000
Rental Income [Member]
Revenue:
Total revenue	1,543,000	1,508,000	3,228,000	3,171,000
Net Investment Income [Member]
Revenue:
Total revenue	197,000	145,000	314,000	274,000
Direct Marketing [Member]
Revenue:
Total revenue	1,572,000	6,070,000	5,566,000	13,002,000
Commission Revenue [Member]
Revenue:
Total revenue	$ 295,000		$ 295,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net loss from continuing operations			$ (46,357,000)	$ (14,361,000)
Adjustments to reconcile net loss from continuing operations to net cash used by operating activities:
Depreciation and amortization			2,647,000	6,425,000
Gain on allowance for obsolescence of inventory				(280,000)
Stock based compensation			268,000	4,000
Income on equity method investment			22,000	211,000
(Gain) loss on investments			30,790,000	(3,823,000)
Change in ROU assets			774,000	(10,202,000)
Change in ROU liabilities			(1,052,000)	10,122,000
Gain on extinguishment of debt		$ (110,000)		(110,000)
Gain on sale of assets				(405,000)
Impairment of notes receivable			3,757,000	1,745,000
Decrease (increase) in assets:
Accounts receivable			2,531,000	(460,000)
Inventory			4,707,000	591,000
Prepaid expenses and other current assets			592,000	1,307,000
Other assets			3,123,000	(312,000)
Increase (decrease) in liabilities:
Accounts payable			(3,846,000)	192,000
Accrued expenses			(15,958,000)	(3,036,000)
Other liabilities			(81,000)	(373,000)
Net cash used by operating activities - continuing operations			(18,083,000)	(13,947,000)
Net cash used by operating activities - held for sale			(1,632,000)
Net cash used by operating activities			(19,715,000)	(13,947,000)
Cash flows from investing activities:
Purchase of property, plant and equipment			(496,000)	(976,000)
Purchase of real estate				(689,000)
Purchase of marketable securities				(4,805,000)
Disposal of property, plant and equipment			215,000	2,557,000
Sale of marketable securities			11,330,000
Issuance of new notes receivable				(3,362,000)
Payments received on notes receivable			2,327,000	863,000
Net cash provided by (used in) investing activities			13,376,000	(6,412,000)
Cash flows from financing activities:
Payments of long-term debt			(5,519,000)	(169,000)
Borrowings of long-term debt			2,601,000	6,360,000
Deferred financing fees
Issuances of common stock, net of issuance costs				1,518,000
Net cash (used in) provided by financing activities			(2,918,000)	7,709,000
Net increase (decrease) in cash - continuing operations			(7,625,000)	(12,650,000)
Net increase (decrease) in cash – held for sale			(1,632,000)
Cash and cash equivalents at beginning of period			19,290,000	56,595,000	$ 56,595,000
Cash and cash equivalents at end of period	$ 10,033,000	$ 43,945,000	$ 10,033,000	$ 43,945,000	$ 19,290,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 1,594,000		$ 294,685,000	$ (134,503,000)	$ 161,776,000	$ 36,409,000	$ 198,185,000
Beginning balance, shares at Dec. 31, 2021	79,746,000
Issuance of common stock, net of expenses	$ 80,000		1,438,000		1,518,000		1,518,000
Issuance of common stock, net of expenses, shares	3,987,000
Net loss				(12,700,000)	(12,700,000)	(1,661,000)	(14,361,000)
Stock based payments	$ 327,000		5,894,000		6,221,000		6,221,000
Stock based payments, shares	16,347,000
Conversion of preferred stock
Ending balance, value at Jun. 30, 2022	$ 2,001,000		302,017,000	(147,203,000)	156,815,000	34,748,000	191,563,000
Ending balance, shares at Jun. 30, 2022	100,080,000
Beginning balance, value at Dec. 31, 2022	$ 2,779,000		317,126,000	(194,343,000)	125,562,000	31,119,000	156,681,000
Beginning balance, shares at Dec. 31, 2022	139,017,000
Issuance of common stock, net of expenses	$ 25,000		243,000		268,000		268,000
Issuance of common stock, net of expenses, shares	1,247,000
Deconsolidation of Sharing Services Global Corp				18,773,000	18,773,000	5,064,000	23,837,000
Net loss				(45,959,000)	(45,959,000)	(398,000)	(46,357,000)
Ending balance, value at Jun. 30, 2023	$ 2,804,000		$ 317,369,000	$ (221,529,000)	$ 98,644,000	$ 35,785,000	$ 134,429,000
Ending balance, shares at Jun. 30, 2023	140,264,000

Nature of Operations and Basis

Nature of Operations and Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Basis of Presentation and Significant Accounting Policies	1. Nature of Operations and Basis of Presentation and Significant Accounting Policies The Company, incorporated in the state of New York in May 1984 has conducted business in the name of Document Security Systems, Inc. On September 16, 2021, the board of directors approved an agreement and plan of merger with a wholly owned subsidiary, DSS, Inc. (a New York corporation, incorporated in August 2020), for the sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This change became effective on September 30, 2021. DSS, Inc. maintained the same trading symbol “DSS” and updated its CUSIP number to 26253C 102. DSS, Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our” or the “Company”) currently operates nine (9) distinct business lines with operations and locations around the globe. These business lines are: (1) Product Packaging, (2) Biotechnology, (3) Direct Marketing, (4) Commercial Lending, (5) Securities and Investment Management, (6) Alternative Trading (7) Digital Transformation, (8) Secure Living, and (9) Alternative Energy. Each of these business lines are in different stages of development, growth, and income generation. Our divisions, their business lines, subsidiaries, and operating territories: (1) Our Product Packaging line is led by Premier Packaging Corporation, Inc. (“Premier”), a New York corporation. Premier operates in the paper board and fiber based folding carton, consumer product packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex 3-dimensional direct mail solutions. Premier is currently located in its new facility in Rochester, NY, and primarily serves the US market. (2) The Biotechnology business line was created to invest in or acquire companies in the BioHealth and BioMedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also targeting unmet, urgent medical needs, and is developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. (3) Direct Marketing, led by the holding corporation, Decentralized Sharing Systems, Inc. (“Decentralized”) provides services to assist companies in the emerging growth “Gig” business model of peer-to-peer decentralized sharing marketplaces. Direct specializes in marketing and distributing its products and services through its subsidiary and partner network, using the popular gig economic marketing strategy as a form of direct marketing. Direct Marketing’s products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific, Middle East, and Eastern Europe. (4) Our Commercial Lending business division, driven by American Pacific Bancorp (“APB”), is organized for the purposes of being a financial network holding company, focused on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting services, and advisory capital raising services. (5) Securities and Investment Management was established to develop and/or acquire assets in the securities trading or management arena, and to pursue, among other product and service lines, broker dealers, and mutual funds management. Also in this segment is the Company’s real estate investment trusts (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. The REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. (6) Alternative Trading was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Alternative Trading, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, and cryptocurrency via an alternative trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). (7) Digital Transformation was established to be a Preferred Technology Partner and Application Development Solution for mid cap brands in various industries including the direct selling and affiliate marketing sector. Digital improves marketing, communications and operations processes with custom software development and implementation. (8) The Secure Living division has developed a plan for fully sustainable, secure, connected, and healthy living communities with homes incorporating advanced technology, energy efficiency, and quality of life living environments both for new construction and renovations for single and multi-family residential housing. (9) The Alternative Energy group was established to help lead the Company’s future in the clean energy business that focuses on environmentally responsible and sustainable measures. Alset Energy, Inc, the holding company for this group, and its wholly owned subsidiary, Alset Solar, Inc., pursue utility-scale solar farms to serve US regional power grids and to provide underutilized properties with small microgrids for independent energy. On May 13, 2021, Sentinel Brokers, LLC. (“Sentinel LLC”), subsidiary of the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 % equity position of Sentinel Brokers Company, Inc. (“Sentinel Co.”), a company registered in the state of New York, and in December 2022, Sentinel LLC exercised this option to increase its equity position to 75 %. Sentinel is a broker-dealer operating primarily as a fiduciary intermediary, facilitating intuitional trading of municipal and corporate bonds as well as preferred stock, and is registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). The accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly our consolidated financial position as of June 30, 2023 and December 31, 2022, and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial statements and the notes included in our latest annual report on Form 10-K for the fiscal year ended December 31, 2022 (“Form 10-K”), and our other reports on file with the Securities and Exchange Commission (the “SEC”). Principles of Consolidation Deconsolidation of Sharing Services Global Corporation - 7 81 s a result, SHRG, whose operations represented a significant portion of our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective as of May 1, 2023 (the “Deconsolidation”). The consolidated statement of operations for the fiscal quarter ended June 30, 2023, therefore includes one month of activity related to SHRG prior to the Deconsolidation. Subsequent to April 30, 2023 the assets and liabilities of SHRG are no longer included within our consolidated balance sheets. Any discussions related to results, operations, and accounting policies associated with SHRG refer to the periods prior to the Deconsolidation. Upon Deconsolidation, we recognized a loss before income taxes of approximately $ 29,196,000 148,000 Reclassifications Use of Estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the accounts receivable, convertible notes receivable, inventory, fair values of investments, intangible assets and goodwill, useful lives of intangible assets and property and equipment, fair values of options and warrants to purchase the Company’s common stock, preferred stock, deferred revenue and income taxes, among others. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Cash Equivalents Accounts/Rents Receivable 3,390,000 29,000 Notes receivable, unearned interest, and related recognition Investments For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments. Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. Inventory 57,000 742,000 Impairment of Long-Lived Assets and Goodwill Business Combinations (Loss) Earnings Per Common Share 3,333 3,556 11,930 Concentration of Credit Risk - As of December 31, 2022, two customers accounted for approximately 14 6 36 17 As of June 30, 2023, two customers accounted for approximately 19 5 55 14 Income Taxes Allowance For Loans And Lease Losses ASU No.2016-13 – Credit Losses” Going Concern 10.0 Aside from its $ 10.0 11.6 9.3 55 15 40.2 The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, continued growth among our operating segments, and tightly controlling operating costs and reducing spending growth rates wherever possible to return to profitability. In addition, the Company has taken steps, and will continue to take measures, to materially reduce the expenses and cash burn at all corporate and business line levels. At the Company’s current operating levels and capital usage, we believe that without any further acquisition or investments, our $ 10.0 11.6 9.3

Revenue

Revenue	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	2. Revenue The Company recognizes its products and services revenue based on when the title passes to the customer or when the service is completed and accepted by the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for shipped product or service provided. Sales and other taxes billed and collected from customers are excluded from revenue. The Company recognizes rental income associated with its REIT, net of amortization of favorable/unfavorable lease terms relative to market and includes rental abatements and contractual fixed increases attributable to operating leases, where collection has been considered probable, on a straight-line basis over the term of the related lease. The Company recognizes net investment income from its investment banking line of business as interest owed to the Company occurs. The Company generates revenue from its direct marketing line of business primarily through internet sales and recognizes revenue as items are shipped. As of June 30, 2023, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the asset that the Company would have otherwise recognized is one year or less. Accounts/Rents Receivable The Company extends credit to its customers in the normal course of business. The Company performs ongoing credit evaluations and generally does not require collateral. Payment terms are generally 30 days but up to net 105 for certain customers. The Company carries its trade accounts receivable at invoice amounts and its rent receivables at contract amounts, less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for doubtful accounts based upon management’s estimates that include a review of the history of past write-offs and collections and an analysis of current credit conditions. At June 30, 2023, and December 31, 2022, the Company established a reserve for doubtful accounts of approximately $ 3,390,000 29,000 3,361,000 Selling, general and administrative (including stock-based compensation) on the accompanying Condensed Consolidation of Operations. Sales Commissions Sales commissions are expensed as incurred for contracts with an expected duration of one year or less. There were no sales commissions capitalized as of June 30, 2023. Shipping and Handling Costs Costs incurred by the Company related to shipping and handling are included in cost of products sold. Amounts charged to customers pertaining to these costs are reflected as revenue. See Note 15 for disaggregated revenue information.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventory	3. Inventory Inventory consisted of the following as of: Schedule of Inventory June 30, 2023 December 31, 2022 Finished Goods $ 3,226,000 $ 6,779,000 Work in Process 749,000 403,000 Raw Materials 1,381,000 1,281,000 Inventory Gross $ 5,357,000 $ 8,463,000 Less allowance for obsolescence (57,000 ) (742,000 ) Inventory Net $ 5,300,000 $ 7,721,000

Notes Receivable

Notes Receivable	6 Months Ended
	Jun. 30, 2023
Receivables [Abstract]
Notes Receivable	4. Notes Receivable Note 1 On February 8, 2021, the Company entered into a convertible promissory note (“Note 1”) with Borrower 1, a company registered in Gibraltar. The Company loaned the principal sum of $ 800,000 4 Note 2 On May 14, 2021, DSS Pure Air, Inc. a subsidiary of the Company entered a convertible promissory note (“Note 2”) with Borrower 2, a company registered in the state of Texas. Note 3 has an aggregate principal balance up to $ 5,000,000 6.65 May 1, 2023 Note 2 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Borrower 2 with the maximum principal amount equal to 18% of the total equity position of Borrower 2 at conversion. 5,544,000 5,420,000 2,884,000 Note 3 On September 23, 2021, APB entered into refunding bond anticipatory note (“Note 3”) with Borrower 3, which operates as a conservation and reclamation district pursuant to Chapter 3891, Texas Special District Local Laws Code; Chapter 375, Texas Local Government Code; and Chapter 49, Texas Water Code. The District Note was in the sum of $ 3,500,000 5.59 September 22, 2022 3,802,000 3,701,000 Note 4 On October 25, 2021, APB entered into a loan agreement (“Note 4”) with Borrower 4, a company registered in the state of Utah. Note 4 has an initial aggregate principal balance up to $ 1,000,000 , to be funded at the request of Borrower 4, with an option to increase the maximum principal borrowing to $ 3,000,000 . Note 4, which incurs interest at a rate of 8.0 % with principal and interest due at the maturity date of October 25, 2022 . This note contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest. APB, as holder of Note 4, has the right to elect one member to the Board of Managers. This note is in default and the outstanding principal and interest of approximately $ 884,000 was reserved for fully as of December 31, 2022. Note 5 On May 14, 2021, APB extended the credit (“Note 5”) to an individual (“Borrower 5”) in the form of two promissory notes for $ 250,000 10,000 12.5 May 15, 2023 262,000 9,000 252,000 9,000 Note 6 On October 27, 2021, HWH World, Inc., a subsidiary of the Company entered a revolving loan commitment (“Note 6”) with Borrower 8, a company registered in Taiwan. The outstanding principal and interest at June 30, 2023 and December 31, 2022 is $ 68,000 63,000 note was amended in April 2022 to borrow up to $ 102,000 18 Note 7 On December 28, 2021, APB entered into a promissory note (“Note 7”) with Borrower 7, a company registered in the state of California. Note 7 has a principal balance of $ 700,000 12.0 December 28, 2022 May 31, 2023 612,000 701,000 Note 8 On January 24, 2022, APB and Borrower 8 entered into a promissory note (“Note 8”) in the principal sum of $ 100,000 6 January 2024 99,000 106,000 Note 9 On March 2, 2022, APB and Borrower 9, a corporation organized under the laws of the Republic of Korea entered into a promissory note (“Note 9”). Under the terms of Note 9, APB at its discretion, may lend up to the principal sum of $ 893,000 8 March 2024 435,000 14,000 874,000 25,000 Note 10 On May 9, 2022, DSS PureAir and Borrower 2 entered into a promissory note (“Note 10”) in the principal sum of $ 210,000 10 February 9, 2023 224,000 213,000 Note 11 On August 29, 2022, DSS Financial Management Inc and Borrower 11 entered into a promissory note (“Note 11A”) in the principal sum of $ 100,000 with interest of 8 %, is due in three quarterly installments beginning on September 14, 2022. All unpaid principal and interest is due on August 29, 2025 . The outstanding principal and interest at June 30, 2023 and December 31, 2023 approximates $ 99,000 , and $ 100,000 is included in Notes receivable on the accompanying consolidate balance sheet. Borrower 11 entered into a second promissory note (Note 11B) on May 8, 2023 in the principal sum of $ 100,000 2 10.25 102,000 Note 12 On July 26, 2022, APB and Borrower 12 entered into a promissory note (“Note 12”) in the principal sum of $ 1,000,000 8 July 26, 2024 861,000 40,000 924,000 66,000 Note 13 On June 15, 2022, Decentralized and Borrower 13 entered into a convertible promissory note (“Note 13”) in the principal sum of $ 27,000,000 8 0.03 June 14, 2024 Note 14 On February 19, 2021, Impact BioMedical, Inc, a subsidiary of the Company, entered into a promissory note (Note 14) with Borrower 14. The Company loaned the principal sum of $ 206,000 6.5 August 19, 2022 204,000 206,000 16,000 190,000 Note 15 On May 8, 2023, DSS Financial Management Inc and Borrower 15 entered into a promissory note (“Note 15”) in the principal sum of $ 102,000 2 10.5 May 5, 2026 102,000 36,000 65,000 Note 16 On June 27, 2023, Decentralized and Borrower 16 entered into a convertible promissory note (“Note 16”) in the principal sum of $ 1,400,000 300,000 10 September, 1, 2024 1,100,000 Note 17 On March 31,2023, DSS Biohealth Security, Inc and Borrower 17 entered into a promissory note (“Note 17”) in the principal sum of $ 140,000 March 31, 2025 127,000 83,000 44,000

Financial Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2023
Investments, All Other Investments [Abstract]
Financial Instruments	5. Financial Instruments Cash, Cash Equivalents, Restricted Cash and Marketable Securities The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of June 30, 2023, and December 31, 2022: Schedule of Cash and Marketable Securities by Significant Investment Category 2023 Unrealized Gain/ Fair Cash and Cash Marketable Cost (Loss) Value Equivalents Securities Cash $ 9,971,000 $ - $ 9,971,000 $ 9,971,000 $ - Level 1 Money Market Funds $ 62,000 - 62,000 62,000 - Marketable Securities 15,165,000 (3,590,000 ) 11,575,000 - 11,575,000 Total $ 25,198,000 $ (3,590,000 ) $ 21,608,000 $ 10,033,000 $ 11,575,000 2022 Unrealized Gain/ Fair Cash and Cash Marketable Cost (Loss) Value Equivalents Securities Investments Cash $ 19,226,000 $ - $ 19,226,000 $ 19,226,000 $ - $ - Level 1 Money Market Funds 64,000 - 64,000 64,000 - - Marketable Securities 36,263,000 (3,659,000 ) 27,307,000 - 27,307,000 - Level 2 Warrants 3,318,000 - 140,000 - - 140,000 Convertible securities 1,023,000 - 39,000 - - 39,000 Total $ 59,894,000 $ (3,659,000 ) $ 46,776,000 $ 19,290,000 $ 27,307,000 $ 179,000 The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio.

Provision for Credit Losses

Provision for Credit Losses	6 Months Ended
	Jun. 30, 2023
Provision For Credit Losses
Provision for Credit Losses	6. Provision for Credit Losses Effective December 31, 2022, the Company adopted amended accounting guidance “ ASU No.2016-13 – Credit Losses” As of December 31, 2022, and June 30, 2023 we have reviewed the entire loan portfolio as well as all financial assets of the Company for the purpose of evaluating the loan portfolio and the loan balances, including a review of individual and collective portfolio loan quality, loan(s) performance, including past due status and covenant defaults, assessment of the ability of the borrower to repay the loan on the loan terms, whether any loans should be placed on nonaccrual or returned to accrual, any concentrations in any single borrower and/or industry that we might need to further manage, and if any specific or general loan loss reserve should be established for the entire loan portfolio or for any specific loan. We analyzed the loan loss reserve from three basis: general loan portfolio reserves; industry portfolio reserves, and specific loan loss reserves. For the three and six months ended June 30, 2023, the Company recorded a Loan loss reserve of approximately $ 3,757,000 General Loan Portfolio Reserve - 145,000 199,000 Industry Portfolio Reserves - Specific Loan Reserves 884,000 . As of December 31, 2022 and June 30, 2023 we have recorded a specific loan loss reserve for the full balance due the Company. As of December 31, 2022 and June 30, 2023, the Company reserved for principal and of $ 27,831,000 2,884,000

Held For Sale Assets and Liabil

Held For Sale Assets and Liabilities	6 Months Ended
	Jun. 30, 2023
Held For Sale Assets And Liabilities
Held For Sale Assets and Liabilities	7. Held For Sale Assets and Liabilities On July 1 st 1000 0.01 711,000 The following table identifies the assets and liabilities of HWH World Inc sale for the period ending June 30, 2023: Schedule of Assets and Liabilities Discontinued Operations June 30, 2023 Current assets: Cash and cash equivalents $ 135,000 Accounts receivable, net 423,000 Inventory 807,000 Current portion of notes receivable 68,000 Prepaid expenses and other current assets 91,000 Total current assets 1,524,000 Property, Plant & Equipment 117,000 Right of use assets 70,000 Other Intangible assets 293,000 Total assets $ 2,004,000 Current liabilities: Accounts payable $ 978,000 Accrued expenses and deferred revenue 21,000 Current Portion of Lease liability 130,000 Total current liabilities 1,129,000 Long Term Lease liability 59,000 Total liabilities $ 1,188,000

Investments

Investments	6 Months Ended
	Jun. 30, 2023
Investments, All Other Investments [Abstract]
Investments	8. Investments Alset International Limited related party The Company owns 127,179,291 4 1,501,000 3,319,000 1,945,000 1,068,000 West Park Capital, Inc. On December 30, 2020, the Company signed a binding letter of intent with West Park Capital, Inc (“West Park”) and TBD where the parties agreed to prepare a note and stock exchange agreement whereby DSS will assign the TBD Note to West Park and West Park shall issue to DSS a stock certificate reflecting 7.5 500,000 BMI Capital International LLC On September 10, 2020, the Company’s wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware corporation (“BMIF”) and BMI Capital International LLC, a Texas limited liability company (“BMIC”) whereas DSS Securities, Inc. purchased 14.9 100,000 10 100,000 24.9 20 22,000 26,000 BMIC is a broker-dealer registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). The Company’s chairman of the board and another independent board member of the Company also have ownership interest in BMIC. BioMed Technologies Asia Pacific Holdings Limited On December 19, 2020, Impact BioMedical, a wholly owned subsidiary of the Company, entered into a subscription agreement (the “Subscription Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 4.99 632,000 Under the terms of the Distribution Agreement, the Company will have exclusive rights to distribute the products within the United States, Canada, Singapore, Malaysia, and South Korea and non-exclusive distribution rights in all other countries. In exchange, the Company agreed to certain obligations, including mutual marketing obligations to promote sales of the products. This agreement is for ten years with a one year auto-renewal feature. Vivacitas Oncology, Inc. On March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the “Vivacitas Agreement #1”) with Vivacitas Oncology Inc. (“Vivacitas”), to purchase 500,000 1.00 1,500,000 1.00 1.00 500,000 2,480,000 2,480,000 250,000 On April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $ 1.00 120,000 On July 22, 2021, the Company exercised 1,000,000 1,000,000 16 100 4,100,000 Stemtech Corporation (Sharing Services Global Corp) In September 2021, the Company’s subsidiary SHRG, Stemtech Corporation (“Stemtech”) and Globe Net Wireless Corp. (“GNTW”) entered into a Securities Purchase Agreement (the “SPA”) pursuant to which SHRG invested $ 1.4 million in Stemtech in exchange for: (a) a Convertible Promissory Note in the amount of $ 1.4 million in favor of the Company (the “Convertible Note”) and (b) a detachable Warrant to purchase shares GNTW common stock (the “GNTW Warrant”). Stemtech is a subsidiary of GNTW. As an inducement to enter into the SPA, GNTW agreed to pay to the SHRG an origination fee of $ 500,000 , payable in shares of GNTW’s common stock. The Convertible Note matures on September 9, 2024 , bears interest at the annual rate of 10 %, and is convertible, at the option of the holder, into shares of GNTW’s common stock at a conversion rate calculated based on the closing price per share of GNTW’s common stock during the 30-dayperiod ended September 19, 2021. The GNTW Warrant expires on September 13, 2024 and conveys the right to purchase up to 1.4 million shares of GNTW’s common stock at a purchase price calculated based on the closing price per share of GTNW’s common stock during the 10-day period ended September 13, 2021. In September 2021, GNTW issued to the Company 154,173 shares of its common stock, or less than 1% of the shares of GNTW then issued and outstanding, in payment of the origination fee. In November 2021, Globe Net Wireless Corp. changed its corporate name to Stemtech Corporation. In connection therewith, the investee’s common stock is now traded under the symbol “STEK”. The SHRG carries its investment in the Convertible Note, the GNTW Warrant and the shares of GNTW common stock at fair value in accordance with GAAP. As of June 30, 2023 and December 31, 2022 the investment in the GNTW Warrant and Convertible Note, were valued at $ 0 and $ 44,000 and $ 0 and $ 39,000 respectively. In September 2021, SHRG entered into a Membership Unit Purchase Agreement pursuant to which the SHRG acquired a 30.75 1,537,000 100

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions	9. Acquisitions Sentinel Brokers Company, Inc. On May 13, 2021, Sentinel Brokers, LLC. (“Sentinel LLC”), subsidiary of the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 300,000 750,000 1,050,000 Investments—Equity Method and Joint Ventures 50.1 75 The following summary, prepared on a proforma basis, combines the consolidated results of operations of the Company with those of Sentinel Co as if the acquisition took place on January 1. The pro forma consolidated results include the impact of certain adjustments. Schedule of Business Acquisition, Pro Forma Information 2022 (unaudited) Revenue $ 49,076,804 Net loss $ (61,680,088 ) Basic loss per share $ (0.55 ) Diluted loss per share $ (0.55 ) We are currently in the process of completing the purchase price accounting and related allocations associated with the acquisition of Sentinel Co. Assets included in this acquisition are cash of $ 3,977,000 344,000 1,000 1,274,000 Sentinel is a broker-dealer operating primarily as a fiduciary intermediary, facilitating intuitional trading of municipal and corporate bonds as well as preferred stock, and is registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”).

Short-Term and Long-Term Debt

Short-Term and Long-Term Debt	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Short-Term and Long-Term Debt	10. Short-Term and Long-Term Debt DSS, Inc Promissory Notes - 200,000 8.0 5.00 200,000 On March 16, 2021, American Medical REIT, Inc. received loan proceeds in the amount of approximately $ 110,000 1 111,000 On May 20, 2021, Premier Packaging entered into master loan and security agreement (“BOA Note”) with Bank of America, N.A. (“BOA”) to secure financing approximating $ 3,710,000 3,172,000 3,406,000 4.63 485,000 2,687,000 On August 1, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $ 6,155,000 5,105,000 4.25 The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5 year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months 2,829,000 4.25 40,000 13.62-acre site. The purchase price has been allocated as $ 4,640,000 1,600,000 325,000 585,000 3 4,696,000 168,000 4,590,000 61,000 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 512,000 3,000,000 On October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 , with interest to be charged at a variable rate to be calculated at the maturity date. The Wilson Loan matures on October 12, 2022 , and contains an auto renewal period of nine months. This loan was funded during March 2022. As of June 30, 2023 $ 1,997,000 is included in the Current portion of long-term debt, net on the consolidated balance sheet. As of December 31, 2022 $ 3,008,000 is included in the Current portion of long-term debt, net on the consolidated balance sheet. On November 2, 2021, AMRE LifeCare entered into a loan agreement (“LifeCare Agreement”) with Pinnacle Bank, (“Pinnacle Bank”) in the amount of $ 40,300,000 62,000,000 32,100,000 12,100,000 1,500,000 15,901,000 1 11 52,407,000 The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28%, with the first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in full 8.46 November 2, 2023 November 2, 2024 40,193,000 270,000 40,380,000 106,000 297,000 2,418,000 In November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”), a related party, for the principal amount of $ 8,350,000 8 matures in December 2023 8,805,000 21,366,177 8,350,000 119,000 455,000 346,000 On March 17, 2022, AMRE Winter Haven, LLC (“AMRE Winter Haven”) and Pinnacle Bank (“Pinnacle”) entered into a term loan (“Pinnacle Loan”) whereas Pinnacle lent to AMRE Winter Haven the principal sum of $ 2,990,000 March 7, 2024 4,500,000 3,200,000 1,000,000 222,000 29,000 5 4,450,000 25 4.28 52,000 2,951,000 interest, net of debt issuance costs of $60,000, approximates $2,952,000 and is included in long-term debt, net on the accompanying consolidated balance sheet at December 31, 2022 . 24,000 153,000 On March 30, 2023, Premier Packaging, a subsidiary of the Company entered into a loan and security agreement with Union Bank & Trust Company for the principal amount of $ 790,000 7.44 14,000 773,000 110,000 663,000 A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to June 30, 2023, are as follows: Schedule of Notes Payable and Long-term Debt Year Amount 2023 $ 47,206,000 2024 3,801,000 2025 858,000 2026 901,000 2027 947,000 Thereafter 711,000

Lease Liability

Lease Liability	6 Months Ended
	Jun. 30, 2023
Lease Liability
Lease Liability	11. Lease Liability The Company has operating leases predominantly for operating facilities. As of June 30, 2023, the remaining lease terms on our operating leases range from less than one to twelve years. Renewal options to extend our leases have not been exercised due to uncertainty. Termination options are not reasonably certain of exercise by the Company. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants. There are no significant finance leases as of June 30, 2023. Future minimum lease payments as of June 30, 2023, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2023 633,000 2024 950,000 2025 803,000 2026 794,000 2027 808,000 2028 824,000 After 4,675,000 Total lease payments 9,487,000 Less: Imputed Interest (1,734,000 ) Present value of remaining lease payments $ 7,753,000 Current $ 633,000 Noncurrent $ 7,120,000 Weighted-average remaining lease term (years) 13.9 Weighted-average discount rate 4.3 % In March of 2022, Premier Packaging began leasing its relocated manufacturing facilities to West Henrietta, New York. This lease contains an escalating payment clause, ranging from $ 61,000 78,000

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies License Agreement In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $ 1,250,000

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders’ Equity	13. Stockholders’ Equity Sales of Equity On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 On March 10, 2022, the Company issued 894,084 340,000 On May 5, 2022, the Company issued 63,205 29,000 On May 25, 2022, the Company issued 15,389,995 5,848,000 On May 17, 2022, the shareholders of the Company approved the issuance of up to 21,366,177 8,350,000 367,000 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 0.41 On April 10, 2023 the Company issued 1,247,078 shares of common stock to Mr. Frank Heuszel, CEO of DSS, pursuant to his employment agreement. These shares were issued to settle a previously recorded liability. Stock-Based Compensation - 2,000

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	6 Months Ended
	Jun. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	14. Supplemental Cash Flow Information The following table summarizes supplemental cash flows for the six-months ended June 30, 2023, and 2022: Schedule of Supplemental Cash Flow Information 2023 2022 Cash paid for interest $ 1,402,000 $ 1,499,000

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment Information	15. Segment Information The Company’s nine businesses lines are organized, managed, and internally reported as five Approximate information concerning the Company’s operations by reportable segment for the three and six months ended June 30, 2023 and 2022 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Product Commercial Direct Three Months Ended June 30, 2023 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 3,626,000 $ 197,000 $ 1,572,000 $ - $ 1,838,000 $ - $ 7,233,000 Interest expense 47,000 - - - 91,000 - 138,000 Interest income - - 280,000 49,000 78,000 - 407,000 Net Loss (income) from continuing operations (205,000 ) (1,213,000 ) (28,074,000 ) (3,934,000 ) (4,413,000 ) 116,000 (37,723,000 ) Capital expenditures 4,000 - (4,000 ) 12,000 7,000 - 19,000 Identifiable assets 23,080,000 41,324,000 7,159,000 49,952,000 71,610,000 9,619,000 202,744,000 Assets held for sale - - 2,004,000 - - - 2,004,000 Product Commercial Direct Three Months Ended June 30, 2022 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 3,599,000 $ 831,000 $ 6,111,000 $ 94,000 $ 823,000 $ 313,000 $ 11,771,000 Interest expense 34,000 - (321,000 ) - 408,000 - 121,000 interest Income 1,000 - 2,000 91,000 34,000 11,000 139,000 Net income (loss) from continuing operations 365,000 25,000 892,000 (673,000 ) (3,332,000 ) (2,687,000 ) (5,410,000 ) Capital expenditures 254,000 - 12,000 - 2,000 1,000 269,000 Identifiable assets 26,688,000 52,416,000 52,267,000 56,524,000 85,436,000 9,617,000 282,948,000 Product Commercial Direct - - - - Six Months Ended June 30, 2023 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 9,661,000 $ 314,000 $ 5,566,000 $ - $ 3,523,000 $ - $ 19,064,000 Interest expense 86,000 - - - 302,000 - 388,000 Interest income - - 285,000 143,000 110,000 - 538,000 Net income (loss) from continuing operations 491,000 (1,777,000 ) (31,260,000 ) (4,782,000 ) (6,441,000 ) (2,588,000 ) (46,357,000 ) Capital expenditures 580,000 - - 17,000 35,000 (19,000 ) 613,000 Identifiable assets 23,080,000 41,324,000 7,159,000 49,952,000 71,610,000 9,619,000 202,744,000 Assets held for sale - - 2,004,000 - - - 2,004,000 Product Commercial Direct Six Months Ended June 30, 2022 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 7,168,000 $ 960,000 $ 13,043,000 $ 94,000 $ 2,497,000 $ 302,000 $ 24,064,000 Interest expense 58,000 - - - 1,441,000 - 1,499,000 Stock based compensation 1,000 - - - - 3,000 4,000 Net income (loss) from continuing operations 323,000 207,000 (3,472,000 ) (1,289,000 ) (5,838,000 ) (4,292,000 ) (14,361,000 ) Capital expenditures 943,000 - 14,000 - 15,000 4,000 976,000 Identifiable assets 26,688,000 52,416,000 52,267,000 56,524,000 85,436,000 9,617,000 282,948,000 The following tables disaggregate our business segment revenues by major source: Printed Products Revenue Information: Schedule of Disaggregation of Revenue Three months ended June 30, 2023 Packaging Printing and Fabrication $ 3,571,000 Commercial and Security Printing 55,000 Total Printed Products $ 3,626,000 Three months ended June 30, 2022 Packaging Printing and Fabrication $ 3,952,000 Commercial and Security Printing 96,000 Total Printed Products $ 4,048,000 Six months ended June 30, 2023 Packaging Printing and Fabrication $ 9,341,000 Commercial and Security Printing 320,000 Total Printed Products $ 9,661,000 Six months ended June 30, 2022 Packaging Printing and Fabrication $ 7,468,000 Commercial and Security Printing 149,000 Total Printed Products $ 7,617,000 Direct Marketing Three months ended June 30, 2023 Direct Marketing Internet Sales $ 1,572,000 Total Direct Marketing $ 1,572,000 Three months ended June 30, 2022 Direct Marketing Internet Sales $ 6,070,000 Total Direct Marketing $ 6,070,000 Six months ended June 30, 2023 Direct Marketing Internet Sales $ 5,566,000 Total Direct Marketing $ 5,566,000 Six months ended June 30, 2022 Direct Marketing Internet Sales $ 13,002,000 Total Direct Marketing $ 13,002,000 Rental Income Three months ended June 30, 2023 Rental income $ 1,543,000 Total Rental Income $ 1,543,000 Three months ended June 30, 2022 Rental income $ 1,508,000 Total Rental Income $ 1,508,000 Six months ended June 30, 2023 Rental income $ 3,228,000 Total Rental Income $ 3,228,000 Six months ended June 30, 2022 Rental income $ 3,171,000 Total Rental Income $ 3,171,000 Net Investment Income Three months ended June 30, 2023 Net Investment Income $ 197,000 Total Investment Income $ 197,000 Three months ended June 30, 2022 Net Investment Income $ 145,000 Total Rental Income $ 145,000 Six months ended June 30, 2023 Net investment income $ 314,000 Total Management fee income $ 314,000 Six months ended June 30, 2022 Net Investment Income $ 274,000 Total Management fee income $ 274,000 Commission Income Three months ended June 30, 2023 Commission income $ 295,000 Total commission income $ 295,000 Three months ended June 30, 2022 Commission income $ - Total commission income $ - Six months ended June 30, 2023 Commission income $ 295,000 Total commission income $ 295,000 Six months ended June 30, 2022 Commission income $ - Total commission income $ -

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	16. Related Party Transactions The Company owns 127,179,291 4 1,501,000 3,319,000 1,945,000 1,068,000 On March 2, 2020, AMRE entered into a $ 200,000 8.0 5.00 200,000 On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (“Seller”) to purchase from the Seller’s its wholly owned subsidiary Impact Oncology PTE Ltd. (“IOPL”) for a purchase price of $ 2,480,000 2,480,000 250,000 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 512,000 3,000,000 On October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 1,997,000 In November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”), a related party, for the principal amount of $ 8,350,000 8 matures in December 2023 8,805,000 21,366,177 8,350,000 119,000 On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 In October 2017, Sharing Services issued a Convertible Promissory Note in the principal amount of $ 50,000 333,333 333,333 0.15 78,635.62 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 0.34 On May 17, 2022, the shareholders of the Company approved the issuance of up to 21,366,177 8,350,000 367,000

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events The Company has evaluated all subsequent events and transactions through August 14, 2023, the date that the condensed consolidated financial statements were available to be issued and noted no subsequent events requiring financial statement recognition or disclosure other than what was identified in Note 7.

Nature of Operations and Basi_2

Nature of Operations and Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation Deconsolidation of Sharing Services Global Corporation - 7 81 s a result, SHRG, whose operations represented a significant portion of our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective as of May 1, 2023 (the “Deconsolidation”). The consolidated statement of operations for the fiscal quarter ended June 30, 2023, therefore includes one month of activity related to SHRG prior to the Deconsolidation. Subsequent to April 30, 2023 the assets and liabilities of SHRG are no longer included within our consolidated balance sheets. Any discussions related to results, operations, and accounting policies associated with SHRG refer to the periods prior to the Deconsolidation. Upon Deconsolidation, we recognized a loss before income taxes of approximately $ 29,196,000 148,000
Reclassifications - Certain amounts on the accompanying condensed consolidated cash flows have been reclassified to conform to current period presentation.	Reclassifications
Use of Estimates	Use of Estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the accounts receivable, convertible notes receivable, inventory, fair values of investments, intangible assets and goodwill, useful lives of intangible assets and property and equipment, fair values of options and warrants to purchase the Company’s common stock, preferred stock, deferred revenue and income taxes, among others. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
Cash Equivalents	Cash Equivalents
Accounts/Rents Receivable	Accounts/Rents Receivable 3,390,000 29,000
Notes receivable, unearned interest, and related recognition	Notes receivable, unearned interest, and related recognition
Investments	Investments For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments.
Fair Value of Financial Instruments	Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost.
Inventory	Inventory 57,000 742,000
Impairment of Long-Lived Assets and Goodwill	Impairment of Long-Lived Assets and Goodwill
Business Combinations	Business Combinations
(Loss) Earnings Per Common Share	(Loss) Earnings Per Common Share 3,333 3,556 11,930
Concentration of Credit Risk	Concentration of Credit Risk - As of December 31, 2022, two customers accounted for approximately 14 6 36 17 As of June 30, 2023, two customers accounted for approximately 19 5 55 14
Income Taxes	Income Taxes
Allowance For Loans And Lease Losses	Allowance For Loans And Lease Losses ASU No.2016-13 – Credit Losses”
Going Concern	Going Concern 10.0 Aside from its $ 10.0 11.6 9.3 55 15 40.2 The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, continued growth among our operating segments, and tightly controlling operating costs and reducing spending growth rates wherever possible to return to profitability. In addition, the Company has taken steps, and will continue to take measures, to materially reduce the expenses and cash burn at all corporate and business line levels. At the Company’s current operating levels and capital usage, we believe that without any further acquisition or investments, our $ 10.0 11.6 9.3

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following as of: Schedule of Inventory June 30, 2023 December 31, 2022 Finished Goods $ 3,226,000 $ 6,779,000 Work in Process 749,000 403,000 Raw Materials 1,381,000 1,281,000 Inventory Gross $ 5,357,000 $ 8,463,000 Less allowance for obsolescence (57,000 ) (742,000 ) Inventory Net $ 5,300,000 $ 7,721,000

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2023
Investments, All Other Investments [Abstract]
Schedule of Cash and Marketable Securities by Significant Investment Category	The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of June 30, 2023, and December 31, 2022: Schedule of Cash and Marketable Securities by Significant Investment Category 2023 Unrealized Gain/ Fair Cash and Cash Marketable Cost (Loss) Value Equivalents Securities Cash $ 9,971,000 $ - $ 9,971,000 $ 9,971,000 $ - Level 1 Money Market Funds $ 62,000 - 62,000 62,000 - Marketable Securities 15,165,000 (3,590,000 ) 11,575,000 - 11,575,000 Total $ 25,198,000 $ (3,590,000 ) $ 21,608,000 $ 10,033,000 $ 11,575,000 2022 Unrealized Gain/ Fair Cash and Cash Marketable Cost (Loss) Value Equivalents Securities Investments Cash $ 19,226,000 $ - $ 19,226,000 $ 19,226,000 $ - $ - Level 1 Money Market Funds 64,000 - 64,000 64,000 - - Marketable Securities 36,263,000 (3,659,000 ) 27,307,000 - 27,307,000 - Level 2 Warrants 3,318,000 - 140,000 - - 140,000 Convertible securities 1,023,000 - 39,000 - - 39,000 Total $ 59,894,000 $ (3,659,000 ) $ 46,776,000 $ 19,290,000 $ 27,307,000 $ 179,000

Held For Sale Assets and Liab_2

Held For Sale Assets and Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Held For Sale Assets And Liabilities
Schedule of Assets and Liabilities Discontinued Operations	The following table identifies the assets and liabilities of HWH World Inc sale for the period ending June 30, 2023: Schedule of Assets and Liabilities Discontinued Operations June 30, 2023 Current assets: Cash and cash equivalents $ 135,000 Accounts receivable, net 423,000 Inventory 807,000 Current portion of notes receivable 68,000 Prepaid expenses and other current assets 91,000 Total current assets 1,524,000 Property, Plant & Equipment 117,000 Right of use assets 70,000 Other Intangible assets 293,000 Total assets $ 2,004,000 Current liabilities: Accounts payable $ 978,000 Accrued expenses and deferred revenue 21,000 Current Portion of Lease liability 130,000 Total current liabilities 1,129,000 Long Term Lease liability 59,000 Total liabilities $ 1,188,000

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2023
Sentinel Brokers Company Inc [Member]
Business Acquisition [Line Items]
Schedule of Business Acquisition, Pro Forma Information	The following summary, prepared on a proforma basis, combines the consolidated results of operations of the Company with those of Sentinel Co as if the acquisition took place on January 1. The pro forma consolidated results include the impact of certain adjustments. Schedule of Business Acquisition, Pro Forma Information 2022 (unaudited) Revenue $ 49,076,804 Net loss $ (61,680,088 ) Basic loss per share $ (0.55 ) Diluted loss per share $ (0.55 )

Short-Term and Long-Term Debt (

Short-Term and Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Notes Payable and Long-term Debt	A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to June 30, 2023, are as follows: Schedule of Notes Payable and Long-term Debt Year Amount 2023 $ 47,206,000 2024 3,801,000 2025 858,000 2026 901,000 2027 947,000 Thereafter 711,000

Lease Liability (Tables)

Lease Liability (Tables)	6 Months Ended
	Jun. 30, 2023
Lease Liability
Schedule of Future Minimum Lease Payments	Future minimum lease payments as of June 30, 2023, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2023 633,000 2024 950,000 2025 803,000 2026 794,000 2027 808,000 2028 824,000 After 4,675,000 Total lease payments 9,487,000 Less: Imputed Interest (1,734,000 ) Present value of remaining lease payments $ 7,753,000 Current $ 633,000 Noncurrent $ 7,120,000 Weighted-average remaining lease term (years) 13.9 Weighted-average discount rate 4.3 %

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jun. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The following table summarizes supplemental cash flows for the six-months ended June 30, 2023, and 2022: Schedule of Supplemental Cash Flow Information 2023 2022 Cash paid for interest $ 1,402,000 $ 1,499,000

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of Operations by Reportable Segment	Approximate information concerning the Company’s operations by reportable segment for the three and six months ended June 30, 2023 and 2022 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Product Commercial Direct Three Months Ended June 30, 2023 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 3,626,000 $ 197,000 $ 1,572,000 $ - $ 1,838,000 $ - $ 7,233,000 Interest expense 47,000 - - - 91,000 - 138,000 Interest income - - 280,000 49,000 78,000 - 407,000 Net Loss (income) from continuing operations (205,000 ) (1,213,000 ) (28,074,000 ) (3,934,000 ) (4,413,000 ) 116,000 (37,723,000 ) Capital expenditures 4,000 - (4,000 ) 12,000 7,000 - 19,000 Identifiable assets 23,080,000 41,324,000 7,159,000 49,952,000 71,610,000 9,619,000 202,744,000 Assets held for sale - - 2,004,000 - - - 2,004,000 Product Commercial Direct Three Months Ended June 30, 2022 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 3,599,000 $ 831,000 $ 6,111,000 $ 94,000 $ 823,000 $ 313,000 $ 11,771,000 Interest expense 34,000 - (321,000 ) - 408,000 - 121,000 interest Income 1,000 - 2,000 91,000 34,000 11,000 139,000 Net income (loss) from continuing operations 365,000 25,000 892,000 (673,000 ) (3,332,000 ) (2,687,000 ) (5,410,000 ) Capital expenditures 254,000 - 12,000 - 2,000 1,000 269,000 Identifiable assets 26,688,000 52,416,000 52,267,000 56,524,000 85,436,000 9,617,000 282,948,000 Product Commercial Direct - - - - Six Months Ended June 30, 2023 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 9,661,000 $ 314,000 $ 5,566,000 $ - $ 3,523,000 $ - $ 19,064,000 Interest expense 86,000 - - - 302,000 - 388,000 Interest income - - 285,000 143,000 110,000 - 538,000 Net income (loss) from continuing operations 491,000 (1,777,000 ) (31,260,000 ) (4,782,000 ) (6,441,000 ) (2,588,000 ) (46,357,000 ) Capital expenditures 580,000 - - 17,000 35,000 (19,000 ) 613,000 Identifiable assets 23,080,000 41,324,000 7,159,000 49,952,000 71,610,000 9,619,000 202,744,000 Assets held for sale - - 2,004,000 - - - 2,004,000 Product Commercial Direct Six Months Ended June 30, 2022 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 7,168,000 $ 960,000 $ 13,043,000 $ 94,000 $ 2,497,000 $ 302,000 $ 24,064,000 Interest expense 58,000 - - - 1,441,000 - 1,499,000 Stock based compensation 1,000 - - - - 3,000 4,000 Net income (loss) from continuing operations 323,000 207,000 (3,472,000 ) (1,289,000 ) (5,838,000 ) (4,292,000 ) (14,361,000 ) Capital expenditures 943,000 - 14,000 - 15,000 4,000 976,000 Identifiable assets 26,688,000 52,416,000 52,267,000 56,524,000 85,436,000 9,617,000 282,948,000
Schedule of Disaggregation of Revenue	Printed Products Revenue Information: Schedule of Disaggregation of Revenue Three months ended June 30, 2023 Packaging Printing and Fabrication $ 3,571,000 Commercial and Security Printing 55,000 Total Printed Products $ 3,626,000 Three months ended June 30, 2022 Packaging Printing and Fabrication $ 3,952,000 Commercial and Security Printing 96,000 Total Printed Products $ 4,048,000 Six months ended June 30, 2023 Packaging Printing and Fabrication $ 9,341,000 Commercial and Security Printing 320,000 Total Printed Products $ 9,661,000 Six months ended June 30, 2022 Packaging Printing and Fabrication $ 7,468,000 Commercial and Security Printing 149,000 Total Printed Products $ 7,617,000 Direct Marketing Three months ended June 30, 2023 Direct Marketing Internet Sales $ 1,572,000 Total Direct Marketing $ 1,572,000 Three months ended June 30, 2022 Direct Marketing Internet Sales $ 6,070,000 Total Direct Marketing $ 6,070,000 Six months ended June 30, 2023 Direct Marketing Internet Sales $ 5,566,000 Total Direct Marketing $ 5,566,000 Six months ended June 30, 2022 Direct Marketing Internet Sales $ 13,002,000 Total Direct Marketing $ 13,002,000 Rental Income Three months ended June 30, 2023 Rental income $ 1,543,000 Total Rental Income $ 1,543,000 Three months ended June 30, 2022 Rental income $ 1,508,000 Total Rental Income $ 1,508,000 Six months ended June 30, 2023 Rental income $ 3,228,000 Total Rental Income $ 3,228,000 Six months ended June 30, 2022 Rental income $ 3,171,000 Total Rental Income $ 3,171,000 Net Investment Income Three months ended June 30, 2023 Net Investment Income $ 197,000 Total Investment Income $ 197,000 Three months ended June 30, 2022 Net Investment Income $ 145,000 Total Rental Income $ 145,000 Six months ended June 30, 2023 Net investment income $ 314,000 Total Management fee income $ 314,000 Six months ended June 30, 2022 Net Investment Income $ 274,000 Total Management fee income $ 274,000 Commission Income Three months ended June 30, 2023 Commission income $ 295,000 Total commission income $ 295,000 Three months ended June 30, 2022 Commission income $ - Total commission income $ - Six months ended June 30, 2023 Commission income $ 295,000 Total commission income $ 295,000 Six months ended June 30, 2022 Commission income $ - Total commission income $ -

Nature of Operations and Basi_3

Nature of Operations and Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended	12 Months Ended
	May 04, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Dec. 31, 2022	May 13, 2021
Product Information [Line Items]
Common share, issued and outstanding, rate	81%
Gain loss on investments		$ 29,196,000		$ 29,196,000
Marketable securities		148,000		148,000
Reserve for doubtful accounts		3,390,000		3,390,000	$ 29,000
Inventory allowance for obsolescence		57,000		57,000	742,000
Cash		10,000,000		10,000,000
Marketable securities		11,575,000		11,575,000	27,307,000
Outstanding principal and interest		9,300,000		9,300,000
Current portion of notes receivable		9,269,000		9,269,000	$ 11,719,000
Sharing Services Global Corp [Member]
Product Information [Line Items]
Sale of stock consideration received on transaction				15,000,000
Pinnacle Bank [Member]
Product Information [Line Items]
Debt instrument, face amount		$ 40,200,000		$ 40,200,000
Impact BioMedical, Inc. [Member]
Product Information [Line Items]
Ownership percentage		55%		55%
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage				19%	14%
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage				55%	36%
Customer Two [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage				5%	6%
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage				14%	17%
Warrant [Member]
Product Information [Line Items]
Anti dilutive securities excluded from computation of EPS		3,333	3,556
Share-Based Payment Arrangement, Option [Member]
Product Information [Line Items]
Anti dilutive securities excluded from computation of EPS			11,930
Sentinel Brokers LLC [Member]
Product Information [Line Items]
Ownership interest rate					75%	24.90%
SHRG [Member]
Product Information [Line Items]
Ownership interest rate	7%

Revenue (Details Narrative)

Revenue (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Reserve for doubtful accounts	$ 3,390,000	$ 3,390,000		$ 29,000
Selling, general and administrative			$ 4,000
Selling, General and Administrative Expenses [Member]
Selling, general and administrative	$ 3,361,000	$ 3,361,000

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished Goods	$ 3,226,000	$ 6,779,000
Work in Process	749,000	403,000
Raw Materials	1,381,000	1,281,000
Inventory Gross	5,357,000	8,463,000
Less allowance for obsolescence	(57,000)	(742,000)
Inventory Net	$ 5,300,000	$ 7,721,000

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Jun. 27, 2023

May 08, 2023

Mar. 31, 2023

Dec. 29, 2022

Aug. 29, 2022

Jul. 26, 2022

Jun. 15, 2022

May 09, 2022

Mar. 02, 2022

Jan. 24, 2022

Dec. 28, 2021

Oct. 25, 2021

Sep. 23, 2021

May 14, 2021

Feb. 19, 2021

Apr. 30, 2022

Mar. 31, 2023

Jun. 30, 2023

Dec. 31, 2022

Jun. 30, 2022

Feb. 08, 2021

Financing Receivable, Modified [Line Items]

Notes receivable current

$ 9,269,000

$ 11,719,000

Principal and interest outstanding

9,300,000

Notes Payable

1,112,000

922,000

Notes payable

47,206,000

47,161,000

Note 1 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 800,000

Prime plus rate percentage

4%

Note 2 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 5,000,000

Prime plus rate percentage

6.65%

Maturity date

May 01, 2023

Debt conversion description

Note 2 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Borrower 2 with the maximum principal amount equal to 18% of the total equity position of Borrower 2 at conversion.

Notes receivable current

$ 5,420,000

$ 5,420,000

5,544,000

Principal and interest outstanding

2,884,000

Note 3 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 3,500,000

Prime plus rate percentage

5.59%

Maturity date

Sep. 22, 2022

Notes receivable current

3,701,000

3,701,000

3,802,000

Note 4 [Member]

Financing Receivable, Modified [Line Items]

Prime plus rate percentage

8%

Maturity date

Oct. 25, 2022

Notes receivable current

884,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 3,000,000

Debt description

This note contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest.

Note 4 [Member] | Maximum [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 1,000,000

Note 5 [Member]

Financing Receivable, Modified [Line Items]

Prime plus rate percentage

12.50%

Maturity date

May 15, 2023

Note 5 [Member] | Promissory Note One [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 250,000

Notes receivable current

262,000

Notes Payable

252,000

252,000

Note 5 [Member] | Promissory Note Two [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 10,000

Notes receivable current

9,000

Notes Payable

9,000

9,000

Note 6 [Member]

Financing Receivable, Modified [Line Items]

Prime plus rate percentage

18%

Notes receivable current

63,000

63,000

68,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 102,000

Debt description

note was amended in April 2022 to borrow up to $102,000 and extend the maturity date through April 2023 bearing interest rate of 18%. The due date of this loan is currently being re-negotiated.

Note 7 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 700,000

Prime plus rate percentage

12%

Maturity date

May 31, 2023

Dec. 28, 2022

Notes receivable current

701,000

701,000

612,000

Note 8 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 100,000

Prime plus rate percentage

6%

Notes Payable

99,000

106,000

Debt instrument, face amount

January 2024

Note 9 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 893,000

Prime plus rate percentage

8%

Debt instrument, face amount

March 2024

Outstanding principal and interest

435,000

Unamortized origination fees

25,000

14,000

Notes payable

874,000

874,000

Note 10 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 210,000

Prime plus rate percentage

10%

Maturity date

Feb. 09, 2023

Notes receivable current

224,000

Notes payable

$ 213,000

Note 11 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 100,000

$ 100,000

Prime plus rate percentage

8%

2%

Maturity date

Aug. 29, 2025

Notes Payable

100,000

100,000

Notes payable

99,000

$ 102,000

Effective rate percentage

10.25%

Note 12 [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 1,000,000

Prime plus rate percentage

8%

Maturity date

Jul. 26, 2024

Outstanding principal and interest

861,000

Unamortized origination fees

40,000

$ 66,000

Notes payable

924,000

Note Thirteen [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 27,000,000

Prime plus rate percentage

8%

Maturity date

Jun. 14, 2024

Conversion price

$ 0.03

NoteFourteen [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 206,000

Prime plus rate percentage

6.50%

Maturity date

Aug. 19, 2022

Outstanding principal and interest

$ 204,000

Notes payable

16,000

$ 206,000

$ 190,000

Note Fifteen [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 102,000

Prime plus rate percentage

2%

Maturity date

May 05, 2026

Notes payable

$ 102,000

Effective rate percentage

10.50%

Notes payable

$ 36,000

Notes payable

$ 65,000

Note Sixteen [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 1,400,000

Prime plus rate percentage

10%

Maturity date

Sep. 01, 2024

Notes payable

1,100,000

Debt Instrument, Unamortized Discount

$ 300,000

Note Seventeen [Member]

Financing Receivable, Modified [Line Items]

Principal amount

$ 140,000

$ 140,000

Maturity date

Mar. 31, 2025

Notes payable

127,000

Notes payable

83,000

Notes payable

$ 44,000

Schedule of Cash and Marketable

Schedule of Cash and Marketable Securities by Significant Investment Category (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Line Items]
Adjusted Cost	$ 25,198,000	$ 59,894,000
Unrealized Gain/(Loss)	(3,590,000)	(3,659,000)
Fair Value	21,608,000	46,776,000
Cash and Cash Equivalents	10,033,000	19,290,000
Current marketable securities	11,575,000	27,307,000
Investments		179,000
Fair Value, Inputs, Level 2 [Member] | Convertible Securities [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost		1,023,000
Unrealized Gain/(Loss)
Fair Value		39,000
Cash and Cash Equivalents
Current marketable securities
Investments		39,000
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost		3,318,000
Unrealized Gain/(Loss)
Fair Value		140,000
Cash and Cash Equivalents
Current marketable securities
Investments		140,000
Cash [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	9,971,000	19,226,000
Unrealized Gain/(Loss)
Fair Value	9,971,000	19,226,000
Cash and Cash Equivalents	9,971,000	19,226,000
Current marketable securities
Investments
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	62,000	64,000
Unrealized Gain/(Loss)
Fair Value	62,000	64,000
Cash and Cash Equivalents	62,000	64,000
Current marketable securities
Investments
Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	15,165,000	36,263,000
Unrealized Gain/(Loss)	(3,590,000)	(3,659,000)
Fair Value	11,575,000	27,307,000
Cash and Cash Equivalents
Current marketable securities	$ 11,575,000	27,307,000
Investments

Provision for Credit Losses (De

Provision for Credit Losses (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Financing Receivable, Past Due [Line Items]
Outstanding principal and interest	$ 9,300,000	$ 9,300,000
General Loan Portfolio Reserve [Member] | American Pacific Bancorp [Member]
Financing Receivable, Past Due [Line Items]
Portfolio reserve		145,000	$ 199,000
Specific Loan Reserves [Member] | American Pacific Bancorp [Member] | Asili LLC [Member]
Financing Receivable, Past Due [Line Items]
Current nonaccrual loan balance		884,000
Resvered principal amount	27,831,000	27,831,000	$ 27,831,000
Outstanding principal and interest	2,884,000	2,884,000
Loan [Member]
Financing Receivable, Past Due [Line Items]
Portfolio loan incurred	$ 3,757,000	$ 3,757,000

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Discontinued Operations (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Total current assets	$ 1,524,000
Current liabilities:
Total current liabilities	1,129,000
Long Term Lease liability	59,000
HWH World Inc [Member]
Current assets:
Cash and cash equivalents	135,000
Accounts receivable, net	423,000
Inventory	807,000
Current portion of notes receivable	68,000
Prepaid expenses and other current assets	91,000
Total current assets	1,524,000
Property, Plant & Equipment	117,000
Right of use assets	70,000
Other Intangible assets	293,000
Total assets	2,004,000
Current liabilities:
Accounts payable	978,000
Accrued expenses and deferred revenue	21,000
Current Portion of Lease liability	130,000
Total current liabilities	1,129,000
Long Term Lease liability	59,000
Total liabilities	$ 1,188,000

Held For Sale Assets and Liab_3

Held For Sale Assets and Liabilities (Details Narrative) - USD ($)	Jul. 01, 2023	Jun. 30, 2023	Dec. 31, 2022
Common stock, par value		$ 0.02	$ 0.02
HWH World Inc [Member] | Sharing Services Global Corporation [Member]
Number of shares, issued	1,000
Common stock, par value	$ 0.01
Gross proceeds	$ 711,000

Investments (Details Narrative)

Investments (Details Narrative) - USD ($)								1 Months Ended	3 Months Ended		6 Months Ended		9 Months Ended	12 Months Ended
	Jul. 22, 2021	Apr. 01, 2021	Mar. 18, 2021	Mar. 15, 2021	Dec. 30, 2020	Dec. 19, 2020	Sep. 10, 2020	Sep. 30, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2021	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Marketable securities									$ 148,000		$ 148,000
Unrealized gain loss on investments											(3,590,000)			$ (3,659,000)
Investments														$ 179,000
Issuance of common stock, net of expenses											268,000	$ 1,518,000
Proceeds from Issuance of common stock												1,518,000
Vivacitas Agreement [Member]
Stock options exercised	1,000,000
Stock options exercised	$ 1,000,000
Investment ownership percentage														100%		100%
Investment Owned, Cost														$ 4,100,000
Common Stock [Member]
Issuance of common stock, net of expenses											$ 25,000	$ 80,000
Issuance of common stock, net of expenses, shares											1,247,000	3,987,000
BMI Capital International LLC [Member]
Issuance of common stock, net of expenses							$ 100,000
Investments equity method									$ 22,000		$ 26,000
Impact Oncology PTE Ltd. [Member]
Owners shares			2,480,000
Options to purchase additional shares			250,000
Consideration transferred			$ 2,480,000
Stemtech Corporation [Member] | Securities Purchase Agreement [Member]
Investments								$ 1,400,000					$ 1,400,000
Consideration transferred													1,400,000
[custom:ConvertiblePromissoryNote-0]								$ 1,400,000					1,400,000
[custom:OriginationFee]													$ 500,000
Debt Instrument, Maturity Date													Sep. 09, 2024
Debt Instrument, Interest Rate, Stated Percentage								10%					10%
Stockholders' Equity, Other Shares													154,173
Class of Warrant or Right, Outstanding														0	0
Convertible Notes Payable														$ 39,000	$ 44,000
DSS Securities, Inc. [Member]
Equity method investment ownership percentage							14.90%
BMI Capital International LLC [Member]
Equity method investment ownership percentage							24.90%
BMI Capital International LLC [Member] | Minimum [Member]
Equity method investment ownership percentage							20%
Bio Med Technologies Asia Pacific Holdings Limited [Member]
Equity method investment ownership percentage						4.99%
Issuance of common stock, net of expenses						$ 632,000
Issuance of common stock, net of expenses, shares						525
Vivacitas Oncology Inc [Member] | Vivacitas Agreement [Member]
Equity method investment ownership percentage														16%
Moji Life LLC [Member] | Membership Unit Purchase Agreement [Member]
Equity method investment ownership percentage								30.75%					30.75%
Payments to acquire equity method investments								$ 1,537,000
Alset International Limited [Member]
Owners shares									127,179,291		127,179,291			127,179,291
Outstanding share percentage														4%
Marketable securities									$ 1,501,000		$ 1,501,000			$ 3,319,000	$ 3,319,000
Unrealized gain loss on investments											1,945,000			1,068,000
Alset International Limited [Member] | Executive Director And Chief Executive Officer [Member].
Unrealized gain loss on investments									1,945,000	$ 1,068,000
West Park Capital Inc [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger					7.50%
Investments									$ 500,000		$ 500,000			$ 500,000
DSS Securities, Inc. [Member]
Issuance of common stock, net of expenses							$ 100,000
Outstanding membership interest							10%
Vivacitas Oncology Inc [Member]
Options to purchase additional shares				1,500,000
Shares issued, price per share				$ 1
Additional price per share				$ 1
Proceeds from Issuance of common stock				$ 500,000
Consideration transferred		$ 120,000
Sale of stock, description		the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021 and March 31, 2022.
Share Price		$ 1
Vivacitas Oncology Inc [Member] | Common Stock [Member]
Options to purchase additional shares				500,000

Schedule of Business Acquisitio

Schedule of Business Acquisition, Pro Forma Information (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares
Business Combination and Asset Acquisition [Abstract]
Revenue | $	$ 49,076,804
Net loss | $	$ (61,680,088)
Basic loss per share | $ / shares	$ (0.55)
Diluted loss per share | $ / shares	$ (0.55)

Acquisitions (Details Narrative

Acquisitions (Details Narrative) - USD ($)	Sep. 30, 2021	May 13, 2021	Jun. 30, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Investments				$ 179,000
Goodwill			$ 57,880,000	60,919,000
Sentinel Brokers Company Inc [Member]
Business Acquisition [Line Items]
Purchae price		$ 300,000
Contribution of capital	$ 750,000
Investments	$ 1,050,000
Sentinel Brokers Company Inc [Member] | Common Class A [Member]
Business Acquisition [Line Items]
Percentage of outstanding common stock		50.10%
American Pacific Bancorp [Member]
Business Acquisition [Line Items]
Assets acquisition for cash				3,977,000
Assets receivables				344,000
Fixed assets				1,000
Goodwill				$ 1,274,000
Sentinel Brokers Company Inc [Member]
Business Acquisition [Line Items]
Ownership percent		24.90%		75%

Schedule of Notes Payable and L

Schedule of Notes Payable and Long-term Debt (Details)	Jun. 30, 2023 USD ($)
Debt Disclosure [Abstract]
2023	$ 47,206,000
2024	3,801,000
2025	858,000
2026	901,000
2027	947,000
Thereafter	$ 711,000

Short-Term and Long-Term Debt_2

Short-Term and Long-Term Debt (Details Narrative)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

May 17, 2022 USD ($) shares

Mar. 17, 2022 USD ($)

Nov. 02, 2021 USD ($)

Oct. 13, 2021 USD ($)

Aug. 01, 2021 USD ($) ft²

Mar. 16, 2021 USD ($)

Nov. 30, 2021 USD ($)

Jun. 30, 2023 USD ($)

Mar. 31, 2023 USD ($)

Jun. 30, 2022 USD ($)

Jun. 30, 2023 USD ($)

Jun. 30, 2022 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2023 USD ($)

Mar. 30, 2023 USD ($)

Dec. 31, 2021 USD ($)

May 20, 2021 USD ($)

Mar. 02, 2020 USD ($) $ / shares

Short-Term Debt [Line Items]

Long term debt current

$ 47,206,000

$ 47,206,000

$ 47,161,000

Payments to acquire assets

496,000

$ 976,000

Interest expense

138,000

$ 121,000

388,000

$ 1,499,000

BMIC Loan [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 3,000,000

512,000

512,000

$ 3,000,000

Maturity date

Oct. 12, 2022

Wilson Loan [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 3,000,000

1,997,000

1,997,000

$ 3,008,000

Maturity date

Oct. 12, 2022

Security Agreement [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

773,000

773,000

$ 790,000

Principal interest percentage

7.44%

Long term debt

663,000

663,000

Long term debt current

110,000

110,000

Interest Expense, Debt

14,000

American Medical REIT Inc. [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 8,350,000

Principal interest percentage

1%

Proceeds from Paycheck Protection Program

$ 110,000

Long term debt

$ 111,000

Premier Packaging Bank Of America NA [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

3,172,000

$ 3,406,000

3,172,000

Principal interest percentage

4.63%

Long term debt

2,687,000

2,687,000

Debt Financing Amount

$ 3,710,000

Long term debt current

485,000

485,000

AMRE Shelton LLC [Member] | Loan Agreement [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 6,155,000

Principal interest percentage

4.25%

Long term debt

4,590,000

4,590,000

Long term debt current

$ 5,105,000

168,000

168,000

Debt instrument description

The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5 year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

$ 2,829,000

Debt effective interest rate percentage

4.25%

Area of Land | ft²

40,000

Payments to acquire assets

4,696,000

Payments to intangible assets

$ 585,000

Debt issuance costs

61,000

61,000

AMRE Shelton LLC [Member] | Loan Agreement [Member] | Facility [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

4,640,000

AMRE Shelton LLC [Member] | Loan Agreement [Member] | Land [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

1,600,000

AMRE Shelton LLC [Member] | Loan Agreement [Member] | Tenant Improvements [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

$ 325,000

AMRE Shelton LLC [Member] | Loan Agreement [Member] | Other Intangible Assets [Member]

Short-Term Debt [Line Items]

Estimated useful life

3 years

Pinnacle Bank [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

40,200,000

40,200,000

Pinnacle Bank [Member] | LifeCare Agreement [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 40,300,000

40,380,000

$ 40,193,000

40,380,000

Debt instrument description

The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28%, with the first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in full

Debt effective interest rate percentage

8.46%

Payments to acquire assets

$ 52,407,000

Payments to intangible assets

$ 15,901,000

Debt issuance costs

106,000

$ 270,000

106,000

Maturity date

Nov. 02, 2023

Purchase price

$ 62,000,000

Interest expense

2,418,000

297,000

Pinnacle Bank [Member] | LifeCare Agreement [Member] | Extended Maturity [Member]

Short-Term Debt [Line Items]

Maturity date

Nov. 02, 2024

Pinnacle Bank [Member] | LifeCare Agreement [Member] | Minimum [Member]

Short-Term Debt [Line Items]

Estimated useful life

1 year

Pinnacle Bank [Member] | LifeCare Agreement [Member] | Maximum [Member]

Short-Term Debt [Line Items]

Estimated useful life

11 years

Pinnacle Bank [Member] | LifeCare Agreement [Member] | Facility [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

$ 32,100,000

Pinnacle Bank [Member] | LifeCare Agreement [Member] | Land [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

12,100,000

Pinnacle Bank [Member] | LifeCare Agreement [Member] | Site Improvements [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

$ 1,500,000

Unsecured Promissory Note [Member] | American Medical REIT Inc. [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 200,000

Principal interest percentage

8%

Class of warrant exercise price per share | $ / shares

$ 5

Warrants and rights outstanding

$ 200,000

Alset Note [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 8,350,000

$ 8,350,000

8,350,000

8,805,000

Principal interest percentage

8%

Long term debt

8,805,000

Interest expense

346,000

455,000

Debt instrument, maturity date description

matures in December 2023

Shares issued for convertible debt | shares

21,366,177

Accrued unpaid interest

$ 119,000

119,000

Pinnacle Loan [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 2,990,000

52,000

52,000

Principal interest percentage

4.28%

Payments to acquire assets

$ 4,450,000

Payments to intangible assets

$ 29,000

Estimated useful life

5 years

Debt issuance costs

$ 2,951,000

2,951,000

Maturity date

Mar. 07, 2024

Purchase price

$ 4,500,000

Interest expense

$ 153,000

$ 24,000

Debt instrument term

25 years

Pinnacle Loan [Member] | Facility [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

$ 3,200,000

Pinnacle Loan [Member] | Land [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

1,000,000

Pinnacle Loan [Member] | Site and Tenant Improvements [Member]

Short-Term Debt [Line Items]

Payments to acquire assets

$ 222,000

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Lease Liability
2023	$ 633,000
2025	803,000
2026	794,000
2027	808,000
2028	824,000
After	4,675,000
Total lease payments	9,487,000
Less: Imputed Interest	(1,734,000)
Present value of remaining lease payments	7,753,000
Current	633,000	$ 796,000
Noncurrent	$ 7,120,000	$ 7,820,000
Weighted-average remaining lease term (years)	13 years 10 months 24 days
Weighted-average discount rate	4.30%

Lease Liability (Details Narrat

Lease Liability (Details Narrative)	1 Months Ended
	Mar. 31, 2022 USD ($)
Minimum [Member]
Operating lease payment	$ 61,000
Maximum [Member]
Operating lease payment	$ 78,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - License Agreement [Member] - Bio Medical [Member]	Mar. 19, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Loss contingency allegations	In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $1,250,000. As of June 30, 2023 and December 31, 2022, no liability has been recorded in relation to the Equivir License as development of the Equivir technology has not begun and no reasonable amount can be estimated
Research and development expense	$ 1,250,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)							3 Months Ended	6 Months Ended
	May 25, 2022	May 17, 2022	May 05, 2022	Mar. 10, 2022	Mar. 09, 2022	Feb. 28, 2022	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Feb. 18, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of common stock, value								$ 268,000	$ 1,518,000
Shares issued for convertible debt, value
Stock Issued During Period, Shares, Acquisitions		17,570,948
Number of option forfeited							2,000
True Partners Capital Holdings Limited [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, Acquisitions		62,122,908
Share Price										$ 0.41
Alset EHome International, Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued for convertible debt		21,366,177
Shares issued for convertible debt, value		$ 8,350,000
Accrued unpaid interest		$ 367,000
Stock Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of common stock					3,986,877	44,619,423
Issued price per share						$ 0.3810
Number of shares of common stock, value					$ 1,519,000	$ 17,000,000
Stock Purchase Agreement [Member] | Alset EHome International, Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of common stock					3,986,877	44,619,423
Issued price per share						$ 0.3810
Number of shares of common stock, value					$ 1,519,000	$ 17,000,000
Employment Agreement [Member] | Heng Fai Ambrose Chan [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of common stock	15,389,995			894,084
Number of shares of common stock, value	$ 5,848,000			$ 340,000
Employment Agreement [Member] | Frank Heuszel [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of common stock			63,205
Number of shares of common stock, value			$ 29,000

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Supplemental Cash Flow Elements [Abstract]
Cash paid for interest	$ 1,402,000	$ 1,499,000

Schedule of Operations by Repor

Schedule of Operations by Reportable Segment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Revenue	$ 7,233,000	$ 11,771,000	$ 19,064,000	$ 24,064,000
Interest expense	138,000		388,000
interest Income	407,000	139,000	538,000	295,000
Net income (loss) from continuing operations	(37,723,000)	(5,410,000)	(46,357,000)	(14,361,000)
Capital expenditures	19,000	269,000	613,000	976,000
Identifiable assets	202,744,000	282,948,000	202,744,000	282,948,000
Assets held for sale	2,004,000		2,004,000
Interest expense	138,000	121,000	388,000	1,499,000
Interest income			538,000
Stock based compensation				4,000
Operating Segments [Member] | Product Packaging [Member]
Segment Reporting Information [Line Items]
Revenue	3,626,000	3,599,000	9,661,000	7,168,000
Interest expense	47,000		86,000
interest Income		1,000
Net income (loss) from continuing operations	(205,000)	365,000	491,000	323,000
Capital expenditures	4,000	254,000	580,000	943,000
Identifiable assets	23,080,000	26,688,000	23,080,000	26,688,000
Assets held for sale
Interest expense		34,000		58,000
Interest income
Stock based compensation				1,000
Operating Segments [Member] | Commercial Banking [Member]
Segment Reporting Information [Line Items]
Revenue	197,000	831,000	314,000	960,000
Interest expense
interest Income
Net income (loss) from continuing operations	(1,213,000)	25,000	(1,777,000)	207,000
Capital expenditures
Identifiable assets	41,324,000	52,416,000	41,324,000	52,416,000
Assets held for sale
Interest expense
Interest income
Stock based compensation
Operating Segments [Member] | Direct Marketing Online Sales [Member]
Segment Reporting Information [Line Items]
Revenue	1,572,000	6,111,000	5,566,000	13,043,000
Interest expense
interest Income	280,000	2,000
Net income (loss) from continuing operations	(28,074,000)	892,000	(31,260,000)	(3,472,000)
Capital expenditures	(4,000)	12,000		14,000
Identifiable assets	7,159,000	52,267,000	7,159,000	52,267,000
Assets held for sale	2,004,000		2,004,000
Interest expense		(321,000)
Interest income			285,000
Stock based compensation
Operating Segments [Member] | Biotechnology [Member]
Segment Reporting Information [Line Items]
Revenue		94,000		94,000
Interest expense
interest Income	49,000	91,000
Net income (loss) from continuing operations	(3,934,000)	(673,000)	(4,782,000)	(1,289,000)
Capital expenditures	12,000		17,000
Identifiable assets	49,952,000	56,524,000	49,952,000	56,524,000
Assets held for sale
Interest expense
Interest income			143,000
Stock based compensation
Operating Segments [Member] | Securities [Member]
Segment Reporting Information [Line Items]
Revenue	1,838,000	823,000	3,523,000	2,497,000
Interest expense	91,000		302,000
interest Income	78,000	34,000
Net income (loss) from continuing operations	(4,413,000)	(3,332,000)	(6,441,000)	(5,838,000)
Capital expenditures	7,000	2,000	35,000	15,000
Identifiable assets	71,610,000	85,436,000	71,610,000	85,436,000
Assets held for sale
Interest expense		408,000		1,441,000
Interest income			110,000
Stock based compensation
Operating Segments [Member] | Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenue		313,000		302,000
Interest expense
interest Income		11,000
Net income (loss) from continuing operations	116,000	(2,687,000)	(2,588,000)	(4,292,000)
Capital expenditures		1,000	(19,000)	4,000
Identifiable assets	9,619,000	9,617,000	9,619,000	9,617,000
Assets held for sale
Interest expense
Interest income
Stock based compensation				$ 3,000

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Total Printed Products	$ 3,626,000	$ 4,048,000	$ 9,661,000	$ 7,617,000
Direct Marketing	1,572,000	6,070,000	5,566,000	13,002,000
Total Rental Income	1,543,000	1,508,000	3,228,000	3,171,000
Total Net Investment Income	197,000	145,000	314,000	274,000
Total Commission income	295,000		295,000
Packaging Printing and Fabrication [Member]
Segment Reporting Information [Line Items]
Total Printed Products	3,571,000	3,952,000	9,341,000	7,468,000
Commercial and Security Printing [Member]
Segment Reporting Information [Line Items]
Total Printed Products	55,000	96,000	320,000	149,000
Direct Marketing Internet Sales [Member]
Segment Reporting Information [Line Items]
Direct Marketing	1,572,000	6,070,000	5,566,000	13,002,000
Rental Income [Member]
Segment Reporting Information [Line Items]
Total Rental Income	1,543,000	1,508,000	3,228,000	3,171,000
Net Investment Income [Member]
Segment Reporting Information [Line Items]
Total Net Investment Income	197,000	145,000	314,000	274,000
Commission Income [Member]
Segment Reporting Information [Line Items]
Total Commission income	$ 295,000		$ 295,000

Segment Information (Details Na

Segment Information (Details Narrative)	6 Months Ended
	Jun. 30, 2023 Segments
Segment Reporting [Abstract]
Number of operating segments	5

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)								1 Months Ended	6 Months Ended		12 Months Ended
	Aug. 09, 2022	May 17, 2022	Mar. 09, 2022	Feb. 28, 2022	Oct. 13, 2021	Mar. 18, 2021	Oct. 31, 2017	Nov. 30, 2021	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2023	Mar. 31, 2023	Jul. 01, 2022	Feb. 18, 2022	Mar. 16, 2021	Mar. 02, 2020
Marketable securities									$ 148,000
Unrealized loss on investment									(3,590,000)		$ (3,659,000)
Purchase price									268,000	$ 1,518,000
Number of shares issued for acquisition		17,570,948
BMIC Loan [Member]
Debt instrument, face amount					$ 3,000,000				512,000		3,000,000
Debt instrument maturity date					Oct. 12, 2022
Wilson Loan [Member]
Debt instrument, face amount					$ 3,000,000				$ 1,997,000			$ 3,008,000
Debt instrument maturity date					Oct. 12, 2022
Stock Purchase Agreement [Member]
Number of shares of common stock			3,986,877	44,619,423
Issued price per share				$ 0.3810
Purchase price			$ 1,519,000	$ 17,000,000
Impact Oncology PTE Ltd. [Member]
Investment owned balance shares						2,480,000
Consideration transferred						$ 2,480,000
Options to purchase additional shares						250,000
True Partners Capital Holdings Limited [Member]
Number of shares issued for acquisition		62,122,908
Share price															$ 0.41
Alset Note [Member]
Debt instrument, face amount		$ 8,350,000						$ 8,350,000			$ 8,805,000		$ 8,350,000
Prime plus rate percentage								8%
Debt instrument maturity date, description								matures in December 2023
Shares issued for convertible debt		21,366,177
Accrued unpaid interest		$ 119,000											119,000
Alset International Limited [Member]
Investment owned balance shares									127,179,291		127,179,291
Warrants percentage									4%
Marketable securities									$ 1,501,000		$ 3,319,000		$ 3,319,000
Unrealized loss on investment									$ 1,945,000		$ 1,068,000
Shares issued for convertible debt		21,366,177
American Medical REIT Inc. [Member]
Debt instrument, face amount		$ 8,350,000
Prime plus rate percentage																1%
Unpaid interest		$ 367,000
American Medical REIT Inc. [Member] | Unsecured Promissory Note [Member]
Debt instrument, face amount																	$ 200,000
Prime plus rate percentage																	8%
Exercise price of warrants																	$ 5
Warrants and rights outstanding																	$ 200,000
HWH International Inc [Member]
Debt instrument, face amount							$ 50,000
Issued price per share							$ 0.15
Conversion of stock							333,333
Warrants to purchase							333,333
Cancelleation of warrants and notes	$ 78,635.62
Alset EHome [Member]
Share price														$ 0.34